Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal) (TA982)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2024
Tofacitinib for treating active ankylosing spondylitis (TA920)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Bimekizumab for treating axial spondyloarthritis (TA918)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2023
Bimekizumab for treating active psoriatic arthritis (TA916)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 October 2023
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023
Upadacitinib for treating active ankylosing spondylitis (TA829)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 September 2022
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis (TA825)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 September 2022
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 August 2022
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 July 2022
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Upadacitinib for treating moderate rheumatoid arthritis (TA744)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 November 2021
Tofacitinib for treating juvenile idiopathic arthritis (TA735)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 October 2021
Ixekizumab for treating axial spondyloarthritis (TA718)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 July 2021
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 July 2021
Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (TA715)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 July 2021
Anakinra for treating Still’s disease (TA685)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2021
Filgotinib for treating moderate to severe rheumatoid arthritis (TA676)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 February 2021
Upadacitinib for treating severe rheumatoid arthritis (TA665)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 December 2020
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2019
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 3 October 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 August 2018
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 January 2018
Sarilumab for moderate to severe rheumatoid arthritis (TA485)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 November 2017
Tofacitinib for moderate to severe rheumatoid arthritis (TA480)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 October 2017
Baricitinib for moderate to severe rheumatoid arthritis (TA466)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 August 2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA445)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 May 2017
Ustekinumab for treating active psoriatic arthritis (TA340)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 3 March 2017Published: 4 June 2015
Apremilast for treating active psoriatic arthritis (TA433)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2017
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor (TA415)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 October 2016
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 September 2016
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 January 2016
Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2015
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip (TA304)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 26 February 2014
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) (TA302)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 November 2013
Tocilizumab for the treatment of rheumatoid arthritis (TA247)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 February 2012
Tocilizumab for the treatment of systemic juvenile idiopathic arthritis (TA238)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2011
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 22 June 2011
Golimumab for the treatment of psoriatic arthritis (TA220)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 April 2011
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2010
Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2010
Bimekizumab for treating ankylosing spondylitis TS ID 10334Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 TS ID 11848Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years TS ID 10237Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deucravacitinib for treating active psoriatic arthritis TS ID 11981Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC